A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 Q1W(Buprenorphine FluidCrystal Subcutaneous Injection Depots) in Adults with Opioid Use Disorder

Grants and Contracts Details

StatusFinished
Effective start/end date10/15/1510/14/17

Funding

  • Braeburn Pharmaceuticals: $600,357.00